Waferix

Novel sublingual wafer platform technology

Superior drug delivery

  • Increased bioavailability
  • Rapid onset of therapeutic action
  • Predictable effect
  • Convenient
  • Fixed unit dose

Patented platform technology

  • Delivers small molecules across a range of indications
  • Globally patented

Proprietary manufacturing process

  • Freeze-dried solid dosage form
  • In-house expertise
  • TGA compliant
  • GMP facility

Repurposing drugs
with WaferiX

Improving the delivery of active compounds

WaferiX is ideal for drugs that:

  • are poorly absorbed when swallowed
  • can only be administered intravenously
  • require rapid onset of action
  • benefit from product life-cycle extension

Repurposed drugs have superior delivery and absorption, improved patient compliance and renewed market exclusivity.

Treating new indications using approved actives

Approved active compounds have established safety and toxicity profiles. We reposition these actives for new indications with unmet medical needs. Leveraging on expedited pathways like FDA 505(b)(2), development risks and costs are lowered with faster speed to market.

We develop innovative therapies that improve the quality of life for patients with pain, chronic diseases and debilitating conditions.

Our Product Portfolio

Pharmaceutical Products

We have a robust pipeline of CNS products that are being developed and clinically evaluated. Our portfolio includes Wafermine (sublingual ketamine) for pain and depression, BnoX (sublingual buprenorphine) for pain, and Wafesil (sublingual sildenafil) for erectile dysfunction.

Medicinal Cannabis Products

Our revolutionary sublingual cannabis wafers for medicinal and supplement use have been awarded “CBD Product of the Year 2020” by the Australian Cannabis Awards.

Nutraceutical Products

Entity, our next-generation nutraceuticals, combine unique, clinically backed formulations and superior delivery for products targeting specific conditions.

Wafermine

Our lead product under development is a sublingual racemic ketamine wafer which is being evaluated for the treatment of acute moderate to severe pain.

Phase 3-ready, positive results in Phase 2b

  • strong analgesic effect
  • safe and tolerable
  • non-opioid with opioid sparing effects
Learn more

Strengths at every stage of the development chain

Fully integrated from R&D, manufacturing, regulatory affairs to sales.

Better Operating Efficiencies

End-to-end service, faster speed to market

Quality Control

Fully licensed, TGA-compliant cGMP facility.

Intellectual Property Protection

Proprietary freeze-drying process supported by highly trained professionals and specialised equipment.

Latest Announcements

View all

27Jul2021: iX Biopharma Ltd is pleased to announce that it has entered into an agreement with medicinal cannabis company Organic Genetics Group Limited...

26Jul2021: iX Biopharma’s rights issue closed on July 19 with valid acceptances and valid excess applications amounting to 196.2 per cent of the shares available for subscription...

12Jul2021: iX Biopharma is exploring the possibility of a spin-off of its pharmaceutical business (including medicinal cannabis) by way of a listing on the Main Board of The Stock Exchange of Hong Kong Limited...